The impact of cardiovascular and lung comorbidities in patients with pulmonary arterial hypertension: A systematic review and meta-analysis
- 12 May 2024
- journal article
- review article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (9) , 1383-1394
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysisThe Journal of Heart and Lung Transplantation, 2022
- Profiles and Treatment Patterns of Patients with Pulmonary Arterial Hypertension on Monotherapy at Experienced CentresESC Heart Failure, 2022
- The impact of cardiovascular comorbidities associated with risk for left heart disease on idiopathic pulmonary arterial hypertension: Data from the Hellenic Pulmonary Hypertension Registry (HOPE)Pulmonary Circulation, 2022
- The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyEuropean Journal of Heart Failure, 2021
- MOOSE Reporting Guidelines for Meta-analyses of Observational StudiesJAMA Surgery, 2021
- Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registryThe Journal of Heart and Lung Transplantation, 2020
- Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trialThe Journal of Heart and Lung Transplantation, 2019
- Pre-Capillary, Combined, and Post-Capillary Pulmonary HypertensionJACC, 2016
- Pulmonary Arterial HypertensionJACC, 2013
- Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2010